Corticosteroids for COVID-19: worth it or not?
Mol Biol Rep
; 49(1): 567-576, 2022 Jan.
Article
in English
| MEDLINE | ID: covidwho-1465892
ABSTRACT
Pathogenesis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induced COVID-19 implied the presence of excessive proinflammatory cytokines and chemokines in patients causing significant morbidity and mortality. To diminish systemic hyper inflammation, a few physicians and researchers have utilized corticosteroids. Corticosteroid implementation has increased after the publication of interim guidelines regarding corticosteroid use in COVID-19 patients by WHO, despite the remaining controversies regarding long-term side effects and disease progression capability of corticosteroids. In different studies, the implementation of corticosteroids on COVID-19 patients revealed controversial results, which require further intensive research. This review will present the current outcomes and possibilities of using corticosteroids to treat COVID-19 patients.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Adrenal Cortex Hormones
/
COVID-19 Drug Treatment
Limits:
Humans
Language:
English
Journal:
Mol Biol Rep
Year:
2022
Document Type:
Article
Affiliation country:
S11033-021-06793-0
Similar
MEDLINE
...
LILACS
LIS